在试验中,ocugen基因治疗使 AMD 病变减少了 31%,达到主要终点. Ocugen gene therapy reduced AMD lesions by 31% in trial, meeting primary endpoint.

Ocugen报告了其基因疗法试验对干燥的与年龄相关的黄斑退化症的12个月积极结果,显示病变生长减少31%. Ocugen reported positive 12-month results from its gene therapy trial for dry age-related macular degeneration, showing a 31% reduction in lesion growth. 治疗达到主要终点,55%的患者出现了超过30%的病变大小减少. The therapy met its primary endpoint, with 55% of patients seeing over a 30% lesion size reduction. 该公司计划在2026年开始第三阶段试验,尽管该公告后股票下跌. The company plans to initiate a Phase 3 trial in 2026, though stock fell following the announcement.